Drug Profile
Epirubicin micelle formulation - NanoCarrier/Kowa
Alternative Names: K-912; NC 6003; NC-6300Latest Information Update: 04 Jan 2022
Price :
$50
*
At a glance
- Originator NanoCarrier
- Developer Kowa; NanoCarrier
- Class Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Soft tissue sarcoma; Solid tumours
Most Recent Events
- 04 Jan 2022 Epirubicin micelle formulation - NanoCarrier/Kowa receives Fast Track designation for Soft tissue sarcoma [IV,Infusion] (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NanoCarrier pipeline, January 2022)
- 28 Sep 2021 Phase I/II trial in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) is still ongoing in USA (IV) (NanoCarrier's pipeline, September 2021)
- 28 Sep 2021 Phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) is still ongoing in USA (IV) (NanoCarrier's pipeline, September 2021)